Skip to main content

Iodine Software

Category: AI in Healthcare

AI-powered software that helps healthcare organizations improve clinical documentation and optimize revenue cycles. Iodine Software was founded in 2010. The company is led by William Chan. Based in Austin, United States. Team size: 501-1000. Total funding raised: $36M. Latest round: Private Equity, Undisclosed, 2021-12, led by Advent International. Key investors include Advent International, Bain Capital Ventures, Silversmith Capital Partners, Valspring Capital.

Founded
2010
Headquarters
Austin, United States
Team size
501-1000
Total funding
$36M

Value proposition

To help healthcare organizations maximize revenue, improve clinical documentation, and streamline operations with advanced clinical AI technology, ultimately stopping revenue leakage and relieving administrative burden.

Products and solutions

IodineCDI (Clinical Documentation Integrity), IodineUM (Utilization Management), IodinePreBill, AwareCDI Suite

Unique value

Iodine Software's uniqueness lies in its proprietary 'Cognitive Emulation' machine learning approach, which combines clinical concepts, evidence-based medicine, and deep machine learning to power its revenue cycle solutions. The company also leverages generative AI to enhance its offerings.

Target customer

Hospitals, health systems, and healthcare organizations

Industries served

Healthcare

Technology advantage

The key technological advantage is the ability of their AI-powered solutions to identify and capture revenue opportunities that are often missed in the healthcare revenue cycle. This leads to significant financial improvement and measurable results for their clients. Their collaboration with OpenAI for generative AI integration further strengthens their technological edge.

How they differentiate

Iodine Software differentiates itself through its proprietary AI technology, Cognitive Emulation™, which is designed to think like a doctor to identify and capture missed revenue opportunities for healthcare organizations. This focus on the mid-revenue cycle, specifically clinical documentation integrity (CDI) and utilization management (UM), allows them to provide highly specialized and impactful solutions.

Main competitors

AGS Health, Innovaccer, Health Catalyst

Key partnerships

Waystar (Acquirer), Advent International, Bain Capital Ventures, Silversmith Capital Partners, Coalition for Health AI (CHAI), OpenAI, AHIMA, HCPro/ACDIS, TrueCode, Norwood, Availity, Gainsight

Notable customers

While specific customer names are not publicly disclosed, Iodine Software serves a wide range of healthcare organizations, including some of the largest and most prestigious health systems in the United States.

Major milestones

Achieved a valuation of over $1 billion in 2021, reaching 'unicorn' status., Acquired by Waystar in 2024 for $1.25 billion to enhance AI-driven healthcare payment solutions., Acquired competitor ChartWise Medical Systems to expand its market reach., Launched innovative solutions such as AwareCDI and a next-generation pre-bill solution to further automate and improve the revenue cycle., Joined the Coalition for Health AI to contribute to the responsible development and deployment of AI in healthcare.

Growth metrics

While specific growth metrics are not public, the company achieved a valuation of over $1 billion in 2021, indicating significant growth and market traction. The acquisition by Waystar for $1.25 billion further validates its strong performance and market leadership.

Market positioning

Iodine Software is positioned as a leader in the healthcare AI and revenue cycle management (RCM) market. The company's acquisition by Waystar for $1.25 billion underscores its strong market position and the value of its technology. It is considered a key player in improving clinical documentation and financial outcomes for hospitals and health systems.

Geographic focus

Iodine Software is headquartered in Austin, Texas, and its primary geographic focus is the United States healthcare market.

Patents and IP

Information regarding patents or specific intellectual property is not publicly available.

About William Chan

William Chan is the Co-Founder and CEO of Iodine Software. He has led the company since its inception in 2010, guiding it to become a leader in healthcare AI technology. Following the acquisition of Iodine Software by Waystar in October 2025, he has continued in his leadership role. Before founding Iodine, he was the Director of Product Management at Advent Software, where he was responsible for product strategy and development for investment management software.

Official website: